Floatz logo

31 assets in Primary Peritoneal Serous Adenocarcinoma

Therapeutic assets addressing Primary Peritoneal Serous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Carboplatin
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P3BBB (72)
Olaparib
Primary Peritoneal Serous Adenocarcinoma
NRG OncologyP3BB (70)
Cediranib
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2/3BB (67)
Letrozole
Primary Peritoneal Serous Adenocarcinoma
NRG OncologyP3BB (67)
Adriamycin
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2/3BB (66)
Cis-Diamminedichloroplatinum Ii
Primary Peritoneal Serous Adenocarcinoma
Ohio State University Comprehensive Cancer CenterP3BB (65)
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Primary Peritoneal Serous Adenocarcinoma
Mayo ClinicP2BB (65)
Cyclophosphamide
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer InstituteP2B (63)
Pembrolizumab
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer InstituteP2B (63)
Nogitecan
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2/3B (61)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter
Primary Peritoneal Serous Adenocarcinoma
Mayo ClinicP2B (58)
Atezolizumab
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2/3B (57)
Docetaxel
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P3B (57)
Adsorbed Purified Pertussis Vaccine
Primary Peritoneal Serous Adenocarcinoma
Mayo ClinicP2CCC (53)
Anetumab Ravtansine
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Copanlisib
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Diphtheria Toxoid
Primary Peritoneal Serous Adenocarcinoma
Mayo ClinicP2CCC (53)
Diphtheria Toxoid Adsorbed
Primary Peritoneal Serous Adenocarcinoma
Mayo ClinicP2CCC (53)
Durvalumab
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Ipilimumab
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Lenvatinib
Primary Peritoneal Serous Adenocarcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Nivolumab
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Pegcetacoplan
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer InstituteP2CCC (53)
Tetanus Toxoid
Primary Peritoneal Serous Adenocarcinoma
Mayo ClinicP2CCC (53)
Cdx 1140
Primary Peritoneal Serous Adenocarcinoma
Roswell Park Cancer InstituteP2CCC (51)
Elimusertib
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Ipatasertib
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P1CC (43)
Adavosertib
Primary Peritoneal Serous Adenocarcinoma
M.D. Anderson Cancer CenterEarly P1C (39)
Avb-001
Primary Peritoneal Serous Adenocarcinoma
Avenge Bio, IncP1/2NR ()
Tolinapant
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)P1/2NR ()